Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Verrica Pharmaceuticals reported a net loss of $35.2 million for the first nine months of 2026, driven by increased R&D and SG&A expenses. The company issued a going concern warning due to an accumulated deficit of $360.2 million and limited cash reserves of $14.4 million, though it recently secured a credit agreement for up to $27.5 million.
Yarrow Bioscience, Inc. reported a net loss of $9.7 million for the third quarter of 2026, driven by $10.7 million in operating expenses. Following a merger, the company significantly strengthened its balance sheet, ending the period with $268.9 million in cash and cash equivalents compared to $100.0 million at the end of 2025.
Sirius XM Holdings Inc. appointed William Twomey as Senior Vice President and Chief Accounting Officer, effective December 1, 2026. His compensation package includes an annual base salary of $450,000, a $75,000 sign-on bonus, and a $500,000 sign-on equity award of restricted stock units vesting over three years. Twomey joins from Xerox Holdings Corporation and previously held senior accounting roles at Paramount Global.
TuHURA Biosciences reported financial results for the third quarter ended September 30, 2026, and provided updates on its Phase 3 immuno-oncology programs. The company highlighted positive preliminary data from its IFx-2.0 study in Merkel cell carcinoma and received FDA clearance to begin a Phase 1b study for its VISTA-inhibiting antibody, TBS-2025. Management noted that operations remain funded through a $50 million credit facility from its largest shareholder.
Term
Q3 2026
“We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda® in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months.”
Dr. James Bianco, President and Chief Executive Officer
“With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events.”
Dr. James Bianco, President and Chief Executive Officer
Jade Biosciences is advancing its pipeline with Jade 301 for Dermatomyositis, leveraging preclinical data showing 2.5-fold higher affinity and 8-fold greater potency than competitor Dazookibart, with a cash runway extending into Q4 2028.
Noodles & Company reported third quarter 2026 financial results, highlighted by a 9.5% increase in system-wide comparable restaurant sales. Despite a 1.0% decrease in total revenue to $120.9 million, the company significantly narrowed its net loss to $2.1 million and expanded its restaurant contribution margin by 350 basis points to 16.7%.
Term
Q3 2026
“We are very excited that our third quarter performance continued our strong sales momentum and margin expansion, underscoring the sustainability of our growth and the impact of the improvements we have made across the business. System-wide comparable sales grew 9.5%, which was our third consecutive quarter above 9.0% and eighth consecutive quarter of positive comparable sales growth.”
Joe Christina, President and Chief Executive Officer
“We have also reduced debt by more than $9.0 million year to date, further strengthening our financial foundation. Our focus remains on making Noodles & Company a more compelling choice for guests and a more profitable business, with disciplined execution that supports durable, outsized long-term growth.”
Joe Christina, President and Chief Executive Officer
Digi Power X reported Q3 2026 revenue of $12.25 million, an 85% increase over the prior quarter, driven by a 400% surge in AI-related revenue. The company ended the period with $119.6 million in cash and digital currencies and expects to close a $200 million credit facility in Q4 2026 to fund its data center expansion.
Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.
Term
Q3 2026
“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”
Joseph Oliveto, President and Chief Executive Officer
Lument Finance Trust reported a net loss attributable to common stockholders of $13.5 million for the third quarter of 2026, primarily driven by a $16.5 million provision for credit losses and $5.2 million in real estate owned impairment. Total assets decreased to $1.08 billion from $1.22 billion at year-end 2025, while the company executed a 1-for-10 reverse stock split in September 2026.
Twenty One Capital reported Q3 2026 financial results, highlighted by a net income of $1.087 billion primarily driven by a $1.093 billion fair-value gain on its Bitcoin holdings. The company ended the quarter with 43,514 Bitcoin and $102.8 million in cash while evaluating new business opportunities across the Bitcoin and energy ecosystems.
Term
Q3 2026
“Our mandate is clear: build a durable, cash-generating business around one of the largest corporate Bitcoin treasuries in the world. A balance sheet is not a business. It is our starting point.”
Raphael Zagury, Chief Executive Officer
“We welcome Bitcoin’s appreciation. But gains from an asset we own are not the same as earnings from businesses we operate. Building the latter is our job.”
Twenty One Capital, Inc. reported a net income of $1.09 billion for the three months ended September 30, 2026, primarily driven by a $1.09 billion gain from the change in fair value of digital assets. However, for the nine-month period, the company recorded a net loss of $186.5 million as digital asset values fluctuated, while maintaining a significant Bitcoin treasury valued at approximately $3.64 billion.
Milestone Scientific reported a net loss of approximately $2.5 million for the nine months ended September 30, 2026, an improvement from a $4.6 million loss in the prior year period. Product sales grew slightly to $7.2 million, while the company significantly reduced operating expenses, particularly in research and development and SG&A.
XTI Aerospace reported Q3 2026 revenue of $35.3 million, a 46.1% increase over proforma Q3 2025 results, driven by strong demand in its Drone Nerds business. The company achieved positive Adjusted EBITDA of $1.6 million and completed a strategic pivot by discontinuing its aircraft business and reducing corporate overhead.
Term
Q3 2026
“Our strategic pivot to focus on our Drone Nerds business is substantially complete. We have discontinued the operation of the XTI aircraft business, rightsized our corporate overhead and are focused on the significant opportunity in the commercial and enterprise drone market.”
Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer
“The growth opportunities we see across our portfolio combined with continued disciplined expense management is expected to lead to the transition to positive ongoing operating cash flows during the fourth quarter of 2026.”
Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer
Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.
Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.
Term
Q3 2026
“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”
Immunic, Inc. reported a net loss of $109.0 million for the nine months ended September 30, 2026, compared to $77.9 million in the prior year, driven by increased research and development and general and administrative expenses. The company significantly strengthened its liquidity, ending the period with $132.0 million in cash following a $187.3 million private placement in February 2026.
Tvardi Therapeutics reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $10.9 million loss in the prior year period. The company strengthened its liquidity by raising $13.3 million through an at-the-market equity facility, ending the quarter with $22.3 million in cash and cash equivalents.
Regis Corporation announced that Kersten Zupfer will step down as Executive Vice President and Chief Financial Officer once a successor is appointed. Ms. Zupfer will remain in a non-officer role for a transition period before her employment terminates, at which point she will receive severance benefits under her existing agreement.
Tvardi Therapeutics reported third quarter 2026 financial results and provided updates on its STAT3 inhibitor pipeline, including plans to advance TTI-109 into clinical development for ulcerative colitis in 2027. The company also confirmed it expects a topline readout for its Phase 1b/2 study of TTI-101 in hepatocellular carcinoma in early Q1 2027.
Term
Q3 2026
“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”
Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi
Fathom Holdings Inc. reported a significant decline in revenue to $88.6 million for Q3 2026 compared to $115.3 million in the prior year, primarily driven by a $12.1 million impairment charge. The company's net loss widened to $21.8 million for the quarter, and total shareholders' equity decreased from $37.4 million at year-end 2025 to $1.8 million as of September 30, 2026.
Hanover Insurance Group President and CEO John C. Roche Sells $3.6M of Stock
John C. Roche, President and CEO, sold 14,422 shares of Hanover Insurance Group, Inc. at $247.93 to $250.00 a share (average $249.39) in 3 transactions, worth $3.6M in total on Nov 12, 2026. Shares held after the trade: 151,224 (-1.9%).
Mammoth Energy Services appointed Bernard “Bernie” Lancaster as President, effective November 9, 2026. Mr. Lancaster previously served as the company's Chief Operating Officer and has held various leadership roles at Mammoth for over a decade. The appointment does not result in any changes to his existing compensation arrangements.
QXO, Inc. reported a significant expansion in net sales to $4.9 billion for the third quarter of 2026, driven by major acquisitions including Beacon Roofing Supply and TopBuild Corp. Despite the revenue growth, the company recorded a net loss for the nine months ended September 30, 2026, as it integrated these large-scale operations and managed increased interest expenses from acquisition-related debt.
SBC Medical Group Holdings reported total revenues of $150.8 million for the nine months ended September 30, 2026, a 12.5% increase year-over-year. Net income for the same period rose to $38.9 million, driven by strong performance in related party revenues and improved operational efficiency.
PowerCompute reported Q3 2026 financial results, achieving net income of $0.4 million compared to a loss in the prior year, driven by fair value gains as Bitcoin prices rose 43%. The company significantly improved its balance sheet by reducing secured debt by 94% and announced the purchase of 600 new S21++ miners to increase hashrate by 10%.
Obook Holdings CEO Chun Kai Wang Buys $13.4K of Stock
Chun Kai Wang, CEO, bought 6,171 shares of Obook Holdings Inc. at $2.17 a share, worth $13.4K in total on Nov 12, 2026. Shares held after the trade: 3,157,147 (+0.2%).
Contango Silver & Gold Inc. reported a net loss of $32.5 million for the nine months ended September 30, 2026, compared to a $12.0 million loss in the prior year, driven by increased exploration and general administrative expenses. Total assets grew significantly to $492.8 million following the Dolly Varden acquisition, which added substantial mineral property and equipment value.
SBC Medical Group reported third quarter 2026 revenue of $59 million, a 35% increase year-over-year, driven by service fee revisions and clinic network expansion. Net income attributable to the company rose 22% to $16 million, while Adjusted EBITDA grew 66% to $28 million. The company's supported clinic network expanded to 293 locations, representing a year-over-year increase of 36 locations.
Term
Q3 2026
“The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA margin of 47%.”
Yoshiyuki Aikawa, Chairman and CEO
“Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently.”
Milestone Pharmaceuticals reported a significant increase in cash and cash equivalents to $144.5 million as of September 30, 2026, following the recognition of an $82.8 million royalty financing obligation. The company's accumulated deficit grew to $511.1 million, reflecting ongoing development and commercialization preparations for CARDAMYST (etripamil) nasal spray.
Nova Minerals reported operational progress for the quarter ended September 30, 2026, including the receipt of $23.9 million to date from a $43.4 million Department of War award. The company secured final permits from the Alaska Department of Natural Resources for its pilot-scale antimony development and is advancing towards a 2027 production target at the Estelle Gold and Critical Minerals Project.